Patents by Inventor Ming-Song Tsai

Ming-Song Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160145577
    Abstract: The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express CD34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.
    Type: Application
    Filed: December 9, 2015
    Publication date: May 26, 2016
    Applicant: SUNSHINE LIFE SCIENCE & TECHNOLOGY CORP.
    Inventors: Daniel Tzu-Bi SHIH, Ming-Song TSAI
  • Patent number: 9234177
    Abstract: The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express CD34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: January 12, 2016
    Assignee: SUNSHINE LIFE SCIENCE & TECHNOLOGY CORP.
    Inventors: Daniel Tzu-Bi Shih, Ming-Song Tsai
  • Publication number: 20120094380
    Abstract: The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express CD34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 19, 2012
    Inventors: Daniel TZU-BI SHIH, Ming-Song Tsai
  • Patent number: 7101710
    Abstract: A method of harvesting mesenchymal stem cells from human amniotic fluid uses a two-stage culture protocol comprising culturing human amniocytes and then culturing mesenchymal stem cells. For culturing human amniocytes, primary amniocyte cultures are set up using routine or standard culture protocol in a cytogenetic laboratory. Non-adherent human amniotic fluids cells in the supernatant medium are collected. For culturing mesenchymal stem cells (“MSC”), the non-adherent cells are centrifuged and then plated with an alpha-modified Minimum Essential Medium supplemented with fetal bovine serum. Incubate with humidified CO2 for MSC growth. Reverse transcription polymerase chain reaction (“RT-PCR”) and immunocytochemical analyses reveal that Oct-4 mRNA and OCT-4 protein expression is detectable in the cultured amniotic fluid mesenchymal stem cells (“AFMSCs”). Under differentiation culture conditions, the AFMSCs can be induced to develop into multi-lineage cells, such as adipocytes, osteocytes, neuronal cells, etc.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: September 5, 2006
    Inventors: Ming-Song Tsai, Shiaw-min Hwang
  • Publication number: 20050118712
    Abstract: A method of isolating mesenchymal stem cells from amniotic fluid using a two-stage culture protocol comprising culturing amniocytes and culturing mesenchymal stem cells. For culturing amniocytes, primary cultures are set up using routine or standard culture protocol in a cytogenetic laboratory. Non-adhering amniotic fluids cells in the supernatant medium are collected. For culturing mesenchymal stem cells, centrifuge the non-adhering cells and plate them with an alpha-modified Minimum Essential Medium supplemented with fetal bovine serum. Incubate with humidified CO2 for MSC growth. RT-PCR and immunocytochemical analyses reveal that Oct-4 mRNA and Oct-4 protein expressions are detectable in the cultured AFMSCs. Under differentiation culture conditions, the AFMSCs can be induced into multi-lineage cells, such as adipocytes, osteocytes, neuronal cells, etc.
    Type: Application
    Filed: May 18, 2004
    Publication date: June 2, 2005
    Inventors: Ming-Song Tsai, Shiaw-min Hwang